GRONINGEN, The Netherlands, July 4, 2012 /PRNewswire/ --
Dr. Cees de Jong (former COO Crucell) appointed Chairman of the Board.
Ms. Annemieke Wouterse (N.O.M.) appointed member of the board.
Polyganics today announced the following appointments:
Dr. Cees de Jong (1961) joins Polyganics Supervisory Board to act as Chairman.
Mr. De Jong was the Chief Operating Officer and a member of the Management Board of Dutch Biotechnology company Crucell till its successful merger with Johnson & Johnson in 2011. Under De Jong's leadership Crucell accelerated its revenue growth and improved profitability significantly.
Before joining Crucell, Mr. De Jong was Group Vice President at Quest International, an ICI company. He was a member of Quest International's Management Board and responsible for turning around the Flavours Division, leading to € 1,8 billion acquisition of Quest by market leader Givaudan. Prior to Quest, he worked as Managing Director of DSM Anti-infectives. In 1989, Mr. de Jong started his career at Gist Brocades where he held several managerial roles of increasing responsibility.
Mr. de Jong holds a Medical Degree as well as an MBA from the Erasmus University Rotterdam.
Ms. Annemieke Wouterse joins Polyganics Supervisory board, representing NOM the regional development agency for the Northern Netherlands. Wouterse is an experienced investment manager, managing over 20 participations including acquisition and valuation responsibilities.
Before joining NOM in 1999 she held various senior consultancy and controller roles in companies like Bakkenist, AVEBE and AkzoNobel. Ms Wouterse holds a bachelor in economics from Erasmus University Rotterdam as well as a controller degree from Free University Amsterdam. She recently completed the supervisory board program at the Nyenrode Business University.
"I am very pleased to welcome in our Board such experienced and highly qualified senior executives", says Chief Executive Officer Maarten Nibbelke. "Cees will strengthen the Board with his extensive international experience and his proven achievements in operational excellence. Annemieke will strengthen the board with her extensive financial background and long lasting relationship between our company and the NOM as one of the initial investors in Polyganics. We are confident that both will make an important contribution to achieve our ambitious development and growth strategy in bioresorbable medical devices.
Mr. de Jong and Ms. Wouterse will be replacing Mr. van Mulukom and Mr. Jensma, both retiring effective today after a long and well appreciated period of contribution to Polyganics"
Polyganics is a privately held biomedical company founded in 1998 as a spin off from the Groningen University in the Netherlands focused on bioresorbable medical devices.
Polyganics develops, manufactures and markets worldwide a range of innovative biomedical products based on Bioresorbable polymers used in various surgical applications with global brands including NASOPORE®, OTOPORE®, NEUROLAC®, VIVOSORB® and C-SEAL®.
For additional inquiries please contact our office in the Netherlands, Ms. Marla Kost; email [email protected] phone +31(0)50-58-86-588.